SINGLE DOSE NEVIRAPINE EXPOSURE DOES NOT AFFECT RESPONSE TO ANTI-RETROVIRAL THERAPY IN HIV-INFECTED AFRICAN CHILDREN AGED <3 YEARS

OBJECTIVES: To assess the impact of exposure to single-dose nevirapine (sdNVP) on virological response in young Ugandan/Zimbabwean children ( 0.3) or NNRTIs (P &gt; 0.1) (n = 88) at week 144. CONCLUSION: Given the limited global availability of lopinavir/ritonavir, its significant formulation challenges in young children, and the significant paediatric treatment gap, tablet fixed-dose-combination NVP-based ART remains a good alternative to syrup lopinavir-based ART for children, particularly those over 1 year and even if exposed to sdNVP.This is an open access article distributed under the Creative Commons Attribution-Non Commercial License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0.